Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM

1. Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022; 23: 493–9. doi: 10.1111/1751-2980.13123 DoganI TastekinD KarabulutS SakarB Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors J Dig Dis 2022 23 493 9 10.1111/1751-2980.13123 Open DOISearch in Google Scholar

2. Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw 2021; 20: 29–36. doi: 10.6004/jnccn.2021.7017 Al-ToubahT PelleE ValoneT HaiderM StrosbergJR Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms J Natl Compr Canc Netw 2021 20 29 36 10.6004/jnccn.2021.7017 Open DOISearch in Google Scholar

3. Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag Res 2022; 14: 3507–23. doi: 10.2147/cmar.S372776 ArriviG VerricoM RobertoM BarchiesiG FaggianoA MarchettiP Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis Cancer Manag Res 2022 14 3507 23 10.2147/cmar.S372776 Open DOISearch in Google Scholar

4. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844–60. doi: 10.1016/j.annonc.2020.03.304 PavelM ÖbergK FalconiM KrenningEP SundinA PerrenA Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2020 31 844 60 10.1016/j.annonc.2020.03.304 Open DOISearch in Google Scholar

5. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors With temozolomide and capecitabine. J Clin Oncol 2005; 23: 4216. doi: 10.1200/jco.2005.23.16_suppl.4216 FineRL FogelmanDR SchreibmanSM Effective treatment of neuroendocrine tumors With temozolomide and capecitabine J Clin Oncol 2005 23 4216 10.1200/jco.2005.23.16_suppl.4216 Open DOISearch in Google Scholar

6. Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 759–67. doi: 10.1530/erc-16-0147 CivesM GhayouriM MorseB BrelsfordM BlackM RizzoA Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors Endocr Relat Cancer 2016 23 759 67 10.1530/erc-16-0147 Open DOISearch in Google Scholar

7. Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study. Neuroendocrinology 2021; 111: 752–63. doi: 10.1159/000510159 WangW ZhangY PengY JinKZ LiYL LiangY A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study Neuroendocrinology 2021 111 752 63 10.1159/000510159 Open DOISearch in Google Scholar

8. Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study). Br J Cancer 2019; 121: 537–44. doi: 10.1038/s41416-019-0558-7 Solis-HernandezMP Fernandez Del ValleA Carmona-BayonasA Garcia-CarboneroR CustodioA BenaventM Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study) Br J Cancer 2019 121 537 44 10.1038/s41416-019-0558-7 Open DOISearch in Google Scholar

9. Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, et al. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol 2014; 20: 218–22. doi: 10.3350/cmh.2014.20.2.218 ChoiJI ImagawaDK BhosaleP BhargavaP TirkesT SeeryTE Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib Clin Mol Hepatol 2014 20 218 22 10.3350/cmh.2014.20.2.218 Open DOISearch in Google Scholar

10. Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34: 823–42. doi: 10.1007/s10555-015-9598-5 Garcia-CarboneroR Garcia-FigueirasR Carmona-BayonasA SevillaI TeuleA QuindosM Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development Cancer Metastasis Rev 2015 34 823 42 10.1007/s10555-015-9598-5 Open DOISearch in Google Scholar

11. Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120: 711–21. doi: 10.1002/cncr.28493 KrajewskiKM NishinoM FranchettiY RamaiyaNH Van den AbbeeleAD ChoueiriTK Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria Cancer 2014 120 711 21 10.1002/cncr.28493 Open DOISearch in Google Scholar

12. Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, et al. Comparison of abdominal MRI with diffusion-weighted imaging to ⁶⁸Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013; 40: 897–907. doi: 10.1007/s00259-013-2371-5 Schmid-TannwaldC Schmid-TannwaldCM MorelliJN NeumannR HaugAR JansenN Comparison of abdominal MRI with diffusion-weighted imaging to ⁶⁸Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas Eur J Nucl Med Mol Imaging 2013 40 897 907 10.1007/s00259-013-2371-5 Open DOISearch in Google Scholar

13. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461–75. doi: 10.1007/s00428-002-0609-x PapottiM BongiovanniM VolanteM AllìaE LandolfiS HelboeL Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 2002 440 461 75 10.1007/s00428-002-0609-x Open DOISearch in Google Scholar

14. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010; 35: 321–8. doi: 10.1097/RLU.0b013e3181d6677c VersariA CamelliniL CarlinfanteG FrasoldatiA NicoliF GrassiE Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study Clin Nucl Med 2010 35 321 8 10.1097/RLU.0b013e3181d6677c Open DOISearch in Google Scholar

15. Singh S, Poon R, Wong R, Metser U. ⁶⁸Ga PET Imaging in patients with neuroendocrine tumors: A systematic review and meta-analysis. Clin Nucl Med 2018; 43: 802–10. doi: 10.1097/rlu.0000000000002276 SinghS PoonR WongR MetserU ⁶⁸Ga PET Imaging in patients with neuroendocrine tumors: A systematic review and meta-analysis Clin Nucl Med 2018 43 802 10 10.1097/rlu.0000000000002276 Open DOISearch in Google Scholar

16. Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, et al. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging 2014; 13: 1–10. doi: 10.2310/7290.2014.00009 KochW AuernhammerCJ GeislerJ SpitzwegC CyranCC IlhanH Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography Mol Imaging 2014 13 1 10 10.2310/7290.2014.00009 Open DOISearch in Google Scholar

17. Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. ⁶⁸Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349–56. doi: 10.2967/jnumed.110.075002 HaugAR AuernhammerCJ WanglerB SchmidtGP UebleisC GokeB ⁶⁸Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors J Nucl Med 2010 51 1349 56 10.2967/jnumed.110.075002 Open DOISearch in Google Scholar

18. Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers 2021; 13. doi: 10.3390/cancers13174321 IngenerfM KieslS KarimS BeyerL IlhanH RübenthalerJ (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE) Cancers 2021 13 10.3390/cancers13174321 Open DOISearch in Google Scholar

19. Filippi L, Scopinaro F, Pelle G, Cianni R, Salvatori R, Schillaci O, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016; 43: 432–40. doi: 10.1007/s00259-015-3178-3 FilippiL ScopinaroF PelleG CianniR SalvatoriR SchillaciO Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours Eur J Nucl Med Mol Imaging 2016 43 432 40 10.1007/s00259-015-3178-3 Open DOISearch in Google Scholar

20. Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ. Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. J Gastrointest Oncol 2014; 5: 247–52. doi: 10.3978/j.issn.2078-6891.2014.019 PeixotoRD NoonanKL PavlovichP KenneckeHF LimHJ Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs J Gastrointest Oncol 2014 5 247 52 10.3978/j.issn.2078-6891.2014.019 Open DOISearch in Google Scholar

21. Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol 2023; 41: 1359–69. doi: 10.1200/jco.22.01013 KunzPL GrahamNT CatalanoPJ NimeiriHS FisherGA LongacreTA Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211) J Clin Oncol 2023 41 1359 69 10.1200/jco.22.01013 Open DOISearch in Google Scholar

22. Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017; 8: 104046–56. doi: 10.18632/oncotarget.22001 OwenDH AlexanderAJ KondaB WeiL HemmingerJA SchmidtCR Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response Oncotarget 2017 8 104046 56 10.18632/oncotarget.22001 Open DOISearch in Google Scholar

23. Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with ⁹⁰Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of ⁶⁸Ga-DOTATOC? Diagn Interv Imaging 2014; 95: 289–300. doi: 10.1016/j.diii.2013.07.006 ÖksüzMÖ WinterL PfannenbergC ReischlG MüssigK BaresR Peptide receptor radionuclide therapy of neuroendocrine tumors with ⁹⁰Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of ⁶⁸Ga-DOTATOC? Diagn Interv Imaging 2014 95 289 300 10.1016/j.diii.2013.07.006 Open DOISearch in Google Scholar

24. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [⁶⁸Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 2015; 17: 313–8. doi: 10.1007/s11307-014-0795-3 KratochwilC StefanovaM MavriopoulouE Holland-LetzT Dimitrakopoulou-StraussA Afshar-OromiehA SUV of [⁶⁸Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors Mol Imaging Biol 2015 17 313 8 10.1007/s11307-014-0795-3 Open DOISearch in Google Scholar

25. Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 2019; 141: 108–15. doi: 10.1016/j.radonc.2019.09.003 SharmaR WangWM YusufS EvansJ RamaswamiR WernigF (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours Radiother Oncol 2019 141 108 15 10.1016/j.radonc.2019.09.003 Open DOISearch in Google Scholar

26. Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers 2020; 12. doi: 10.3390/cancers12113314 SiricoM BernocchiO SobhaniN GiudiciF CoronaSP VernieriC Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer Cancers 2020 12 10.3390/cancers12113314 Open DOISearch in Google Scholar

27. Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57: 355–60. doi: 10.2967/jnumed.115.165613 MichlM LehnerS PaprottkaPM IlhanH BartensteinP HeinemannV Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer J Nucl Med 2016 57 355 60 10.2967/jnumed.115.165613 Open DOISearch in Google Scholar

28. Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, et al. Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters. Biomedicines 2022; 10. doi: 10.3390/biomedicines10102618 IngenerfM KieslS WinkelmannM AuernhammerCJ RübenthalerJ GraweF Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters Biomedicines 2022 10 10.3390/biomedicines10102618 Open DOISearch in Google Scholar

29. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753–9. doi: 10.1200/jco.2006.07.3049 ChoiH CharnsangavejC FariaSC MacapinlacHA BurgessMA PatelSR Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 2007 25 1753 9 10.1200/jco.2006.07.3049 Open DOISearch in Google Scholar

30. Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinology 2018; 14: 656–69. doi: 10.1038/s41574-018-0082-5 HoflandJ ZandeeWT de HerderWW Role of biomarker tests for diagnosis of neuroendocrine tumours Nat Rev Endocrinology 2018 14 656 69 10.1038/s41574-018-0082-5 Open DOISearch in Google Scholar

31. Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, et al. Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management – an updated review. Frontiers Oncol 2020; 10: 831. doi: 10.3389/fonc.2020.00831 BocchiniM NicoliniF SeveriS BongiovanniA IbrahimT SimonettiG Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management – an updated review Frontiers Oncol 2020 10 831 10.3389/fonc.2020.00831 Open DOISearch in Google Scholar

32. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 111–34. doi: doi.org/10.1016/j.ecl.2010.12.001 LawrenceB GustafssonBI KiddM PavelM SvejdaB ModlinIM The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 2011 40 111 34 doi: doi.org/10.1016/j.ecl.2010.12.001 Search in Google Scholar

33. Strosberg JR, Cives M, Brelsford M, Black M, Meeker A, Ghayouri M. Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. J Clin Oncolog 2015; 33: 4099. doi: 10.1200/jco.2015.33.15_suppl.4099 StrosbergJR CivesM BrelsfordM BlackM MeekerA GhayouriM Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors J Clin Oncolog 2015 33 4099 10.1200/jco.2015.33.15_suppl.4099 Open DOISearch in Google Scholar

34. Spada F, Antonuzzo L, Marconcini R, Gelsomino F, Fumagalli C, Messerini L, et al. Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multi-center retrospective analysis. J Clin Oncol 2015; 33: e15174-e. doi: 10.1200/jco.2015.33.15_suppl.e15174 SpadaF AntonuzzoL MarconciniR GelsominoF FumagalliC MesseriniL Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multi-center retrospective analysis J Clin Oncol 2015 33 e15174-e 10.1200/jco.2015.33.15_suppl.e15174 Open DOISearch in Google Scholar

35. O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016; 280: 576–84. doi: 10.1148/radiol.2016142043 OJH LodgeMA WahlRL Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0 Radiology 2016 280 576 84 10.1148/radiol.2016142043 Open DOISearch in Google Scholar

36. Opalińska M, Morawiec-Sławek K, Kania-Kuc A, Al Maraih I, Sowa-Staszczak A, Hubalewska-Dydejczyk A. Potential value of pre- and post-therapy [⁶⁸Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022; 13: 929391. doi: 10.3389/fendo.2022.929391 OpalińskaM Morawiec-SławekK Kania-KucA Al MaraihI Sowa-StaszczakA Hubalewska-DydejczykA Potential value of pre- and post-therapy [⁶⁸Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors Front Endocrinol 2022 13 929391 10.3389/fendo.2022.929391 Open DOISearch in Google Scholar

37. Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE. J Nuclear Med 2020; 61: 217–21. doi: 10.2967/jnumed.119.228072 IlanE VelikyanI SandströmM SundinA LubberinkM Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE J Nuclear Med 2020 61 217 21 10.2967/jnumed.119.228072 Open DOISearch in Google Scholar